Literature DB >> 9326994

Abnormal skeletal muscle bioenergetics in familial hypertrophic cardiomyopathy.

C H Thompson1, G J Kemp, D J Taylor, M Conway, B Rajagopalan, A O'Donoghue, P Styles, W J McKenna, G K Radda.   

Abstract

OBJECTIVE: To determine the skeletal muscle metabolic manifestations of familial hypertrophic cardiomyopathy.
DESIGN: A case-control study.
SETTING: 31P magnetic resonance spectroscopy of the calf muscle was performed on volunteers from a centre specialising in familial hypertrophic cardiomyopathy. PATIENTS: Five patients with abnormal beta myosin heavy chain protein in cardiac and skeletal muscle and five patients with a troponin T abnormality in cardiac muscle were compared with healthy controls.
RESULTS: High energy phosphate metabolism in vivo was examined in a non-invasive manner. In resting muscle, the beta myosin heavy chain group had a higher ratio of phosphocreatine to ATP concentration (4.51 (SD 0.17)) than either the troponin T group (3.88 (0.42)) or controls (n = 16; 4.04 (0.40)). Exercise duration was reduced compared to controls, and during the fourth minute of exercise phosphocreatine depletion and muscle acidification were greater in both patient groups. After exercise, the recovery of phosphocreatine-an index of oxidative metabolic capacity of the muscle-was slower in the beta myosin heavy chain group (mean half time 0.65 (0.08) minutes) than in the troponin T group (0.60 (0.17) minutes) or controls (0.48 (0.14) minutes).
CONCLUSIONS: Exercise metabolism was abnormal in both groups of subjects, and the affected contractile protein determined the metabolic changes in muscle at rest and during recovery. In patients with abnormal beta myosin heavy chain protein, there was a decrease in oxidative capacity consistent with the reduction in mitochondria reported in muscle biopsy studies of similar patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326994      PMCID: PMC484900          DOI: 10.1136/hrt.78.2.177

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  16 in total

Review 1.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

Authors:  B J Maron; R O Bonow; R O Cannon; M B Leon; S E Epstein
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

2.  Phosphorus nuclear magnetic resonance of fast- and slow-twitch muscle.

Authors:  R A Meyer; T R Brown; M J Kushmerick
Journal:  Am J Physiol       Date:  1985-03

3.  Metabolic recovery after exercise and the assessment of mitochondrial function in vivo in human skeletal muscle by means of 31P NMR.

Authors:  D L Arnold; P M Matthews; G K Radda
Journal:  Magn Reson Med       Date:  1984-09       Impact factor: 4.668

4.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy.

Authors:  H Watkins; A Rosenzweig; D S Hwang; T Levi; W McKenna; C E Seidman; J G Seidman
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

5.  Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy.

Authors:  L Fananapazir; M C Dalakas; F Cyran; G Cohn; N D Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

6.  Voluntary muscle involvement in hypertrophic cardiomyopathy. A study of eleven patients.

Authors:  E R Smith; L P Heffernan; V E Sangalang; L M Vaughan; C S Flemington
Journal:  Ann Intern Med       Date:  1976-11       Impact factor: 25.391

7.  Energy-rich phosphates in slow and fast human skeletal muscle.

Authors:  K Vandenborne; G Walter; L Ploutz-Snyder; R Staron; A Fry; K De Meirleir; G A Dudley; J S Leigh
Journal:  Am J Physiol       Date:  1995-04

8.  Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy.

Authors:  G Cuda; L Fananapazir; W S Zhu; J R Sellers; N D Epstein
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

9.  Skeletal muscle bioenergetics in the chronic fatigue syndrome.

Authors:  P R Barnes; D J Taylor; G J Kemp; G K Radda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-06       Impact factor: 10.154

10.  Severe functional limitation in patients with hypertrophic cardiomyopathy and only mild localized left ventricular hypertrophy.

Authors:  P Spirito; B J Maron; R O Bonow; S E Epstein
Journal:  J Am Coll Cardiol       Date:  1986-09       Impact factor: 24.094

View more
  2 in total

1.  Heterologous expression of wild-type and mutant beta-cardiac myosin changes the contractile kinetics of cultured mouse myotubes.

Authors:  Gaynor Miller; Joanne Maycock; Ed White; Michelle Peckham; Sarah Calaghan
Journal:  J Physiol       Date:  2003-02-07       Impact factor: 5.182

2.  R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level.

Authors:  K A Palmiter; M J Tyska; J R Haeberle; N R Alpert; L Fananapazir; D M Warshaw
Journal:  J Muscle Res Cell Motil       Date:  2000       Impact factor: 2.698

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.